Among infectious diseases, tuberculosis is the leading cause of death, killing around 3 million people each year. Most cases occur in young adults but it is also a major cause of illness and death in children. The problem has been exacerbated in recent years by the HIV pandemic and by the emergence of multidrug resistance. Co-infection with HIV greatly enhances the risk of overt tuberculosis and in 1999 it is expected that tuberculosis will account for 30% of the predicted 2.5 million AIDS-related deaths. By inducing clinically and radiologically atypical forms of tuberculosis, and by increasing pressure on diagnostic facilities by sheer numbers, serious diagnostic difficulties are increasingly occurring in both adults and children in the tropics. At the present time, 2% of all cases of tuberculosis are multidrug resistant but, as the treatment of such cases is often grossly inadequate in many tropical countries, their frequency will doubtless grow. There are no simple solutions to the global emergency of tuberculosis: clearly there is a need for better use of available control measures but there is also a need to reach a much clearer understanding of the underlying immune phenomena in this disease so as to develop more effective vaccines and therapeutic agents. Finally, it cannot be ignored that tuberculosis is a disease ofpoverty-95% of cases and 98% of deaths due to it occur in the developing nations-and thus a major control measure is a resolution of the gross inequities in health care provision both between and within nations.
Introduction
The 17th century English evangelist John Bunyan termed tuberculosis 'the Captain of all of these Men of Death' and todav. desoite the availabilitv of effective therapy, this epithet is S;ill appropriate in many parts of the world. The reason is that this disease is now out of control in most developing countries and 2 serious problems adding to the emergency have arisen in recent years: the human immunodeficiency virus (HIV) pandemic and multidrug-resistant tuberculosis. So threatening is the situation that, in 1993, the World Health Organization took the unprecedented step of declaring tuberculosis a global emergency (WHO, 1994) . Since then, the incidence has continued to rise and urgent and concerted action is thus required to avert a tragedy on an unprecedented scale early in the new millennium.
The global burden of tuberculosis
Human tuberculosis is caused by members of the Mycobacterium tuberculosis complex, principally M. tuberculosis (and the closely related M. africanurn in some parts of Africa) but disease due to M. bovis (the bovine tubercle bacillus) occurs in some countries where cattle tuberculosis has not been eliminated. Infection usually occurs by inhaling small droplets of cough aerosol, about 5 pm in diameter, containing tubercle bacilli. Infection by M. bovis is also acquired by drinking infected milk, leading to primary lesions in the pharynx or intestine.
A third of the human population, i.e., about 2000 million persons, have been infected by M. tuberculosis (WHO. 1998) and are at risk of develonina the disease later in life. The number actually develo$ngdisease each year is over 7 million (Figure) . Each year, around 3 million people die of tuberculosis, mostly young adults in developing countries, and it is an important cause of morbidity and mortality among children (CHINTU & ZUMLA, 1997) . Being a chronic disease, with less than a quarter of patients receiving adequate therapy, there may be as many as 20 million active cases at any given time. About half of these have transmissible forms of the *Author for correspondence; fax +44 (0) 17 1 35 1 8443; e-mail j.grange@ic.ac.uk disease and infect at least 100 million people each year. Tuberculosis is a disease of poverty: 95% of cases and 98% of deaths due to it occur in the developing nations.
Factors affecting susceptibility to tuberculosis The concept of racial or 'innate' immunity is controversial. Tuberculosis was rampant in Europe in the last century and its relative rarity nowadays may, the impact of improved housing and nutrition not withstanding, reflect a well-adapted co-existence in contrast to Africa where exposure is comparatively more recent. Any cause of immunosuppression predisposes to the development of tuberculosis while, in addition to BCG vaccination, varying levels of protection have been attributed to natural exposure to mycobacteria in the environment (FINE, 1995) .
There are differences in susceptibility to tuberculosis, and in the type of disease that develops, in children of different ages (DONALD et al., 1999) . Those aged under 5 years are susceptible but they develop consolidation and pneumonia without cavitation or caseous necrosis. Between the ages of 5 and 10 years (i.e., during adrenarche) children appear to be resistant to the disease despite continuing exposure demonstrated by an increasing incidence of tuberculin-test positivity. This agerange was thus known as the 'safe school age' in 19th century Europe, and the phenomenon is now seen in high incidence areas such as Cape Town. Finally, susceptibility returns at puberty, with the disease resembling that seen in adults, with cavitation and necrosis.
These changes suggest an underlying endocrinological cause, and hypotheses as to how endocrine factors may affect immune responses have been developed (ROOK et al., 1997) .
HIV/AIDS pandemic and its effects on tuberculosis control Over the past decade, infection by HIV has emerged as by far the most important of the factors known to increase the risk of an infected person developing tuberculosis (WHO, 1996) . While non-immunocompromised people who overcome the primary infection have about a 5% chance of developing post-primary tuberculosis later in life, the chance rises to 50% in the HIV-positive person.
As those infected with HIV have a shortened life expectancy, the annual risk of developing tuberculosis is around 8%-over 20 times higher than in HIV-negative persons infected by the tubercle bacillus (DOLIN et al., 1994 ). An HIV-infected person may also be infected or reinfected by exposure to a tuberculosis source case. The risk of developing tuberculosis is then very high and progression to clinically active disease is 'telescoped' down to a few months rather than years. As a result, there have been a number of explosive mini-epidemics-a phenomenon that originally indicated the seriousness of the impact of HIV infection on the epidemiology of tuberculosis. In 1998, there were an estimated 33 million HIV-positive persons worldwide (UNAIDS, 1998). Assuming that one-third are co-infected with tubercle bacilli and thus have an 8% annual chance of developing tuberculosis, an additional million cases of this disease are expected in 1999, with 70% occurring in subSaharan Africa. Tuberculosis is expected to account for 30% of the predicted 2.5 million AIDS-related deaths in 1999 (UNAIDS, 1998), with the major impact being felt in sub-Saharan Africa. In 1994, autopsy studies showed that, in Africa, 38% of all HIV-positive cadavers and 43-54% of those dying with AIDS-defining conditions had active tuberculosis (LUCAS & NELSON, 1994) . The frequency is now certainly higher and HIV-related tuberculosis is therefore having a devastating effect on health services and societal structure in this continent. In Zambia, 1 in 4 pregnant women are infected with HIV (FYLKESNES et al., 1997) and tuberculosis is now one of the top non-obstetric causes of maternal death.
Understanding
immune responses in tuberculosis An understanding of the immune responses and mechanisms of protection in tuberculosis is essential for the development of novel vaccines and immunotherapeutic strategies but, despite extensive and elaborate research programmes, progress has been slow.
The immune response to initial infection with M. tuberculosis restricts its replication and spread in most cases but dissemination of bacilli via lymphatics and the bloodstream may lead to foci of disease elsewhere in the body. Many factors, including disturbances of nonspecific and specific host immune responses, determine whether the initial lesions resolve or progress to overt primary tuberculosis. Both non-specific and specific effector mechanisms appear to play a role in immunity to tuberculosis.
There is evidence that the outcome of tuberculosis is closely related to the balance between Thl and Th2 lymphocyte responses, with protective immunity being Thl-mediated and a superimposed Th2 response being harmful (NEWPORT et al., 1996; ROOK & HERNANDEZ-PANDO, 1996; COOPER et al., 1997) .
Most mycobacteria are probably killed by macrophages activated by cytokines such as interferon gamma (IFNy) produced by Thl lymphocytes, although the actual killing mechanism in humans is not known. Whatever the mechanism, a key feature of the immune response against M. tuberculosis is the formation of granulomas which are dynamic structures characterized by the accumulation of activated macrophages and infiltration by T lymphocytes. Though primarily restricting the spread of the infection, granuloma formation can also contribute to destruction of surrounding normal tissues. The morphological features of granulomas and the extent of their formation vary considerably and a wide spectrum of reactions is seen in tuberculosis (RIDLEY & RIDLEY, 1986) . At one end of this spectrum, immunocompromised individuals show poor granulomatous responses but instead show extensive necrotic lesions containing large numbers of mycobacteria. At the other extreme, immunocompetent patients with indolent paucibacillary forms of tuberculosis, such as lupus vulgaris, display florid non-caseating granulomas containing few organisms. Most tuberculosis patients fall in between these 2 extremes. The factors contributing to granuloma formation in tuberculosis are noorlv understood but cytokines, notably Thl cytokines, play a prominent role (ROOK & HERNANDEZ-PANDO, 1996) . By contrast, immunosuppression and the production of Th2 cytokines is associated with impaired granuloma formation.
The characteristic feature of active tuberculosis is tissue necrosis but the underlying mechanism, and its relation to protective immunity, has been the topic of much debate since it was first documented by Robert Koch in the 1890s (KOCH, 189 1). There is evidence that such necrosis is associated with tumour necrosis factor (TNFa), a cytokine produced during the immune response to tuberculosis. According to one hypothesis, too much TNFa causes tissue damage as well as symptoms of tuberculosis, such as fever and weight loss (KAPLAN, 1994) . Alternatively, TNFa may become damaging, not because it is in excess but because a Type 2 component to the immune reaction renders tissues highly susceptible to killing by TNFa, thereby leading to extensive necrosis instead of protective granuloma formation (ROOK & HERNANDEZ-PANDO, 1996) . This might explain why, as mentioned above, protective immunity to tuberculosis requires a Type 1 response but the addition of a Type 2 response opposes protection.
The complex series of interactions between mycobacteria, immunocompetent cells and their secreted cytokines and, possibly, endocrine effects underlies the variety of presentations of tuberculosis seen in clinical practice. The pathogenesis of tuberculosis should be viewed as an interplay between the macrophage-activating Thl protective immune response and the mechanisms that lead to tissue damage. Despite an enormous literature on the subject, neither the processes nor the relationship between them are yet fully understood.
Interactions between tuberculosis and HIV infection
It is recognized that HIV infection increases the chance of developing tuberculosis and modifies its clinical course. Conversely, development of tuberculosis in coinfected persons accelerates progression to full-blown AIDS and enhances HIV replication leading to marked increases in plasma viral loads. A likely mechanism is the activation of latently HIV-infected cells, with virus expression and replication, by cytokines produced in response to infection with M. tuberculosis (GOLETTI et al., 1998) .
In general, HIV-positive patients with relatively intact immunity develop typical caseating granulomas and tissue necrosis leading to cavity formation. In the more profoundly immunosuppressed, both these tissue reactions are suppressed so that diffuse infiltrations teeming with acid-fast bacilli are seen and dissemination to other organs is common.
Clinical features of tuberculosis in the era of HIV The diagnosis of tuberculosis still depends on a high index of suspicion and broad knowledge of its clinical features, but co-infection with HIV can have a profound effect on the clinical presentation, as well as the course, of the disease (CHIN-W & ZUMLA, 1997). Atvnical nresentations are more likely in the-more 'prof&dly*immunosuppressed and include a higher proportion of extrapulmonary disease such as miliary tuberculosis, lesions affecting the lymph nodes, bone and skin and disseminated disease. Chest radiographs are frequently atypical (SAKS & POSNER, 1992) , the tuberculin skin test is often negative and there is a lower frequency of sputum-smear positivitv. The incidences of adverse reactions to a&-tuberculosis drugs, mortality and relanse are also increased. The clinical differences in children between HIV-positive and HIV-negative cases are, however, not as striking as in adults.
Changing pattern of tuberculosis in HIV-infected children
There is a lack of reliable clinical criteria for the specific diagnosis of respiratory infections in children, and the changing clinical patterns of respiratory illnesses in children consequent to the HIV pandemic have made the accurate diagnosis of tuberculosis and assessing the prevalence of the disease even more difficult (CHLNTU & DONALD et al., 1999) .
In Zambia and West Africa a high proportion of children presenting at clinics and hospitals have respiratory illnesses which are not easilv diagnosed as their signs and symptoms are similar (Ii0 et-al., 1994; SASS&I-MORORRO et al., 1994; LUCAS et al., 1996; VETTER et al., 1996) . The problem is exacerbated in HIV-infected children as several opportunistic infections, such as Pneumocystis carinii pneumonia, have clinical and radiological features in common with tuberculosis (TUMBA et al., 1997). Diagnostic difficulties notwithstanding, there is substantial evidence for an increasing prevalence of HIV-related tuberculosis in children in several developing countries (MUGANGA et al., 1991; Luo et al., 1994; SASSAN-MORORRO et al., 1994; VE-ITER et al., 1996) . In Zambia, the incidence of HIV positivity among children admitted to hospital with tuberculosis rose from 18% to 67% over an 8-year period, compared to a steady rate of about 10% in children admitted for various surgical conditions (CHIN-W & ZUMLA, 1997).
Diagnostic procedures As outlined above, the diagnosis of tuberculosis is not easy, especially in children. The 'gold standard' of diagnosis in developing countries is microscopy, but it is frequently negative in children and often not readily applicable to non-pulmonary tuberculosis. In addition, maintaining quality and safety in smear microscopy services in remote and resource-poor settings (the very places where incidence of tuberculosis is likely to be greatest) remains a challenge (COLLINS et al., 1997) .
In view of these problems and those associated with cultivation of the tubercle bacillus, and the generally disappointing results of serodiaanostic tests, interest has largeiy turneh to molecular methods, notably those based on the amnlification of mvcobacterial DNA or RNA. Despite in&al problems, these methods are rapid, sensitive and specific-in most circumstances (TAN etal., 1997) . Molecular methods also nermit the ranid detection of rifampicin resistance (DR~BNLEWSKI d WILSON, 1998) . Although some tests are now available commercially, their current cost and infrastructural requirements prevent their implementation in those areas of the world where tuberculosis is most prominent.
Treatment
of tuberculosis Tuberculosis is among the most cost-effective of all diseases to treat (MURRAY et al., 1990 ); a 6-month course of anti-tuberculosis drugs costs only UKAl8. Also, by curing 1 infectious patient, transmission of disease to several others is prevented.
The most effective of the recommended regimens is a 6-month course of rifampicin and isoniazid with the addition of pyrazinamide and ethambutol (or streptomycin) during the first 2 months. In some developing countries, for economic reasons, the initial 2-month phase with quadruple therapy is followed bv isoniazid and ethambutol for an additional 6 months: With the increased toxicitv of thiacetazone in HIV-infected individuals and the high seroprevalence of HIV in developing countries, the use ofthis drug is not recommended.
Treatment and prophylaxis of tuberculosis in HIV-positive persons
The treatment of tuberculosis in HIV-positive individuals follows the same well-established nrincinles used in the treatment ofnon-HIV-infected ind&iduaL (reviewed by SCOTT & DARBYSHIRE, 1997) . As patients with HIV infection are more likely to relapse or acquire a new infection, preventive anti-tuberculosis therapy, although not formally evaluated as a strategy, may be desirable after a full course of treatment.
There has been considerable debate over the provision of prophylactic anti-tuberculosis chemotherapy for coinfected persons, in view of their high risk of developing active tuberculosis (MSAAWJGA & FAWZI, 1997) . The rationale of prophylaxis is not disputed: a systematic review (WILKINSON et al., 1998 ) and a recent study in Zambia (MWINGA et al.. 1998 ) have demonstrated that chemoprophylaxis significantly lowers the risk of tuberculosis in co-infected adults. It is practical issues, such as the establishment of facilities for the diagnosis of dual infection, the risk of emergence of drug resiitance and the provision of supervised prophylactic therapy without breaching confidence, that have posed serious barriers to the implementation of chemoprophylaxis on a wide scale.
Drug-resistant tuberculosis
Resistance to antituberculosis drugs may either be the consequence of the selective growth of drug-resistant mutants (secondary or acquired resistance) or due to infection by a bacillus that is already resistant to one or more dtugs (initial or primary resistance). Acquired resistance develops when therapy is suboptimal due to avoidable factors such as intermittent drug supplies, poor quality drugs or combination preparations, poor prescribing practices, unsupervised therapy and unregulated sale of drugs. Primary resistance occurs when transmission of disease from resistant source cases is poorly controlled.
By generally accepted definition, multidrug resistance is resistance to the principal first-line drugs, isoniazid and rifampicin, with or without resistance to other drugs (KOCHI et al., 1993) . The detection of drug resistance requires good laboratory facilities, a high standard of training and regular quality control (COLLINS et al., 1997) . Thus, documentation on resistance in manv developing countries is limited and sporadic. Never&& less, a global survey has been completed and shows that, with very marked regional variation, around 10% of all isolates show some form of resistance and 2% are multidrug resistant. For full details see the report by WHO (1997) .
Operational aspects of tuberculosis control The aims of tuberculosis control programmes are 3-fold: to cure the patient, to reduce transmission and to prevent the emergence of drug resistance. The usual strategy is to treat those found to be smear-positive on sputum microscopy, and therefore the most infectious. Evaluations of this strategy in Vietnam and China indicate that it reduces the incidence of tuberculosis in a community (jOCHEM & WALLEY, 1999) . In contrast, a recent study in Botswana, a country where HIV infection is common, showed a climbing incidence of tuberculosis despite extensive implementation of the DOTS strategy and a low incidence of drug resistance (KENYON et al., 1999) . We should therefore be cautious about the claim that it is the 'medical breakthrouah of the 1990s' (KOCHI, 1997).
The principles of the WHO DOTS strategy are not contentious. Difficulties are. however. as outlined above. encountered in maintaining-the quality of sputum micro: scopy as a case-detection strategy and also in ensuring access to care, esneciallv for those most disadvantaged: women, the young, the poor and those who are geogranhicallv. culturallv, economicallv and raciallv isolated. In addition, the DdTS strategy directs chemotherapy at patients with smear-positive pulmonary disease, leaving little guidance on how to identify and manage smearnegative and extrapulmonary cases. Although less important than smear positives as sources of infection, transmission from smear-negatives cannot be ignored (BEHR et al., 1999 ). Unless we increase access to chemotherapy we are unlikely to control transmission. The question is how to do this without compromising programme outcomes.
The fifth element, from which the name of the strategy is derived, has come under criticism for not addressing local societal issues such as perception of disease and its treatment, the generation of stigma and the disruptive impact of regular supervision on everyday life and work. Thus there is a strong case for modifying this element of the strategy in the light of local studies by social scientists and anthropologists (OGDEN, 1999 ).
An additional controversial issue is whether govemment support for tuberculosis control should be based on centralized 'vertical' national programmes or should be part of decentralized, 'horizontal', public health services. This has led to considerable tension as donor agencies favour the centralized approach with direct accountability to a nominated director while the 'neo-liberal' philosophies espoused by the World Bank favour decentralization and privatization of health facilities. While this argument continues, the poor and powerless-amongst whom tuberculosis flourishes-are increasingly denied access to even the most rudimentary health care in many regions (GHAULET, 1998) .
Finally, modem short-course therapy fails to address the issue of multidrug-resistant tuberculosis and may even magnify the problem by inducing resistance to the other drugs in the regimen. Accordingly, a 'DOTS-plus' strategy, involving the prescription of empirical or laboratorv-guided regimens suitable for treating such resistance, has been advocated (FARMER d KIM, 1998) . Unfortunatelv, multidrua-resistant tuberculosis requires prolonged and directly Observed treatment with a range of second-line drugs and the cost of such treatment in terms of drugs and supportive services is much higher than standard therapy, which already places a high financial burden on the overstretched health services of many countries.
The future
The incidence of tuberculosis is rising in the developing and the developed world and will continue to do so until there is a radical change in the global approach to this disease. Such a change could be brought about by advances in immunology and molecular biology, particularly the recent sequencing of the entire genome of M. tuberculosis (COLE & BARRE& 1998), which raise hones for the development of novel .vaccines, diagnostic tests and 'designer drugs'.
But we do not know when, or even if, these hopes will be translated into reality. In the meantime, fuelled by the HIV pandemic and the continuing suboptimal control efforts, the entire world could be faced with a massive epidemic of tuberculosis, including many multidrugresistant cases, and the cost of combating it could run into billions of pounds.
While every effort must be made to strengthen and support national and international tuberculosis control efforts, slavish adherence to all elements of the WHO control strategy is not the answer in the short-to-medium term. We need, urgently, to make room for creative innovation in service delivery for patients with tuberculosis.
Finally, it must never be forgotten that this disease has always been, and still is, associated with poverty and deprivation.
Thus, the eventual eradication of this ancient scourge will surely go hand in hand with the creation of a caring global society and the ending of the present gross inequity that scandalizes the human race (ZLJMLA & GRANGE, 1998) .
